![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR)
|
|
|
Reported by Jules Levin
HepDART, Wailea, HI. Dec 6-10, 2015
Ernest Asante-Appiah, Ira Jacobsen, Peggy Wong, Todd Black, Anita Howe, Janice Wahl, Michael N. Robertson, Bach-Yen Nguyen, Melissa Shaughnessy, Peggy Hwang, Eliav Barr and Daria Hazuda
AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
AASLD: Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)
![AASLD1.gif](../images/122215/122215-7/AASLD1.gif)
![AASLD2.gif](../images/122215/122215-7/AASLD2.gif)
![AASLD3.gif](../images/122215/122215-7/AASLD3.gif)
![AASLD4.gif](../images/122215/122215-7/AASLD4.gif)
![AASLD5.gif](../images/122215/122215-7/AASLD5.gif)
![AASLD6.gif](../images/122215/122215-7/AASLD6.gif)
![AASLD7.gif](../images/122215/122215-7/AASLD7.gif)
![AASLD8.gif](../images/122215/122215-7/AASLD8.gif)
![AASLD9.gif](../images/122215/122215-7/AASLD9.gif)
![AASLD10.gif](../images/122215/122215-7/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|